BrainStorm Cell Therapeutics Inc. (BCLI) stock
BCLIOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.77−0.01 (-1.17%)
Close on Oct 19, 2026Market cap $8.50MP/E –Yield –
BrainStorm Cell Therapeutics shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
BrainStorm Cell Therapeutics's shares outstanding was 11M at Jun 30, 2026. For fiscal 2025 it was 9M, up 84.6% from the year before. Over ten years it grew 22.4% a year on average. The highest annual figure on record is 9M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9M | +84.6% |
| FY2024 | Dec 31, 2024 | 5M | +74.9% |
| FY2023 | Dec 31, 2023 | 3M | +18.0% |
| FY2022 | Dec 31, 2022 | 2M | +0.9% |
| FY2021 | Dec 31, 2021 | 2M | +21.2% |
| FY2020 | Dec 31, 2020 | 2M | +36.3% |
| FY2019 | Dec 31, 2019 | 1M | +9.5% |
| FY2018 | Dec 31, 2018 | 1M | +6.5% |
| FY2017 | Dec 31, 2017 | 1M | +0.6% |
| FY2016 | Dec 31, 2016 | 1M | +1.4% |
| FY2015 | Dec 31, 2015 | 1M | +34.7% |
| FY2014 | Dec 31, 2014 | 1M | +27.2% |
| FY2013 | Dec 31, 2013 | 1M | +17.1% |
| FY2012 | Dec 31, 2012 | 1M | +14.6% |
| FY2011 | Dec 31, 2011 | 1M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 11M | +28.0% |
| Q1 FY2026 | Mar 31, 2026 | 11M | +74.0% |
| Q4 FY2025 | Dec 31, 2025 | 11M | +93.7% |
| Q3 FY2025 | Sep 30, 2025 | 11M | +107.3% |
| Q2 FY2025 | Jun 30, 2025 | 9M | +81.6% |
| Q1 FY2025 | Mar 31, 2025 | 6M | +46.9% |
| Q4 FY2024 | Dec 31, 2024 | 6M | +66.1% |
| Q3 FY2024 | Sep 30, 2024 | 5M | +80.0% |
| Q2 FY2024 | Jun 30, 2024 | 5M | +79.4% |
| Q1 FY2024 | Mar 31, 2024 | 4M | +76.2% |
| Q4 FY2023 | Dec 31, 2023 | 3M | +40.7% |
| Q3 FY2023 | Sep 30, 2023 | 3M | +21.3% |
| Q2 FY2023 | Jun 30, 2023 | 3M | +8.8% |
| Q1 FY2023 | Mar 31, 2023 | 2M | +0.8% |
| Q4 FY2022 | Dec 31, 2022 | 2M | +0.9% |
| Q3 FY2022 | Sep 30, 2022 | 2M | +0.5% |
| Q2 FY2022 | Jun 30, 2022 | 2M | +0.5% |
| Q1 FY2022 | Mar 31, 2022 | 2M | +1.8% |
| Q4 FY2021 | Dec 31, 2021 | 2M | +9.0% |
| Q3 FY2021 | Sep 30, 2021 | 2M | +16.5% |
| Q2 FY2021 | Jun 30, 2021 | 2M | +24.1% |
| Q1 FY2021 | Mar 31, 2021 | 2M | +25.9% |
| Q4 FY2020 | Dec 31, 2020 | 2M | +46.5% |
| Q3 FY2020 | Sep 30, 2020 | 2M | +40.0% |
| Q2 FY2020 | Jun 30, 2020 | 2M | +34.9% |
| Q1 FY2020 | Mar 31, 2020 | 2M | +35.9% |
| Q4 FY2019 | Dec 31, 2019 | 2M | +9.7% |
| Q3 FY2019 | Sep 30, 2019 | 1M | +7.6% |
| Q2 FY2019 | Jun 30, 2019 | 1M | +11.3% |
| Q1 FY2019 | Mar 31, 2019 | 1M | +9.8% |
| Q4 FY2018 | Dec 31, 2018 | 1M | +9.7% |
| Q3 FY2018 | Sep 30, 2018 | 1M | +10.2% |
| Q2 FY2018 | Jun 30, 2018 | 1M | +4.1% |
| Q1 FY2018 | Mar 31, 2018 | 1M | +1.9% |
| Q4 FY2017 | Dec 31, 2017 | 1M | +1.1% |
| Q3 FY2017 | Sep 30, 2017 | 1M | +0.7% |
| Q2 FY2017 | Jun 30, 2017 | 1M | – |
| Q1 FY2017 | Mar 31, 2017 | 1M | – |
| Q4 FY2016 | Dec 31, 2016 | 1M | – |
| Q3 FY2016 | Sep 30, 2016 | 1M | – |
See a number that looks wrong?